James F. Jordan
President and CEO
Significant changes in the Life Sciences industry:
On the treatment side, we are moving beyond providing acute care to a greater emphasis on disease management. But to achieve this, greater collaboration has to happen between companies and markets that have traditionally considered themselves competitors. On the business side, analytics will become increasingly important to sales. As health care changes, the complexity of the value chain will continue to change. It’s not just verticals anymore, but more horizontal, meaning more partnerships beyond what has been the norm. Also, with the new ICD-11 coding standards digitizing health care to a greater degree, non-health care companies will be able to seamlessly enter this market, creating new opportunities for partnerships.
How does your prior career experience benefit your role today?
I began working in finance, then through a series of opportunities, moved through operations management, manufacturing, engineering, supervising plant managers, quality assurance, marketing, and OEM sales. That comprehensive progression of responsibilities has provided enormously valuable perspective and experience to help our startups. They are challenged with simultaneously balancing and successfully executing product development and testing, customer satisfaction, and the needs of both investors and potential acquirers.
What makes this work fulfilling?
I’ve been fortunate to have served in a number of consulting roles over the years, and watching individuals and organizations achieve the necessary convergences and partnerships to achieve success has always been extremely rewarding.